Top

Published in:

Open Access 01-12-2008 | Short report

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

Authors: Bernhard Berger, Claus Belka

Published in: Radiation Oncology | Issue 1/2008

Abstract

The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study population, several reports indicate a possible overlap between radiation dermatitis and the EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition of cetuximab to radiotherapy.

Available only for authorised users

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354: 567-578. 10.1056/NEJMoa053422CrossRefPubMed

Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006, 6: 803-812. 10.1038/nrc1970CrossRefPubMed

Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, Guillot B: Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004, 151: 238-241. 10.1111/j.1365-2133.2004.06026.xCrossRefPubMed

Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, Van Cutsem E, Layton A: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005, 3: 599-606. 10.1111/j.1610-0387.2005.05058.xCrossRefPubMed

Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20: 110-124. 10.1200/JCO.20.1.110CrossRefPubMed

Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22: 1201-1208. 10.1200/JCO.2004.10.182CrossRefPubMed

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351: 337-45. 10.1056/NEJMoa033025CrossRefPubMed

Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD: Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005, 23: 1125-1135. 10.1200/JCO.2005.07.010CrossRefPubMed

Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004, 22: 3003-3015. 10.1200/JCO.2004.11.061CrossRefPubMed

10.

Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22: 3238-3247. 10.1200/JCO.2004.11.057CrossRefPubMed

11.

Budach W, Bölke E, Homey B: Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007, 357: 514-515. 10.1056/NEJMc071075CrossRefPubMed

12.

Mydin AR, Armstrong JG: Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol 2007, 85: 171. 10.1016/j.radonc.2007.04.034CrossRefPubMed

13.

Lacouture ME, Hwang C, Marymont MH, Patel J: Temporal dependence of the effect of radiation on erlotinib-induced skin rash. J Clin Oncol 2007, 25: 2140. 10.1200/JCO.2006.09.4045CrossRefPubMed

14.

Bonner JA, Ang K: More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 2007, 357: 1872-1873. 10.1056/NEJMc076359CrossRefPubMed

15.

Mitra SS, Simcock R: Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 2006, 24: 28-29. 10.1200/JCO.2005.05.1631CrossRef

16.

Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK: Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008, 19: 142-149. 10.1093/annonc/mdm400CrossRefPubMed

Title: Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
Authors: Bernhard Berger
Claus Belka
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2008
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-3-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma

Impact of different leaf velocities and dose rates on the number of monitor units and the dose-volume-histograms using intensity modulated radiotherapy with sliding-window technique

High-dose-rate brachytherapy for soft tissue sarcoma in children: a single institution experience

In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol

SCLC extensive disease – treatment guidance by extent or/and biology of response?

Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT